专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO2007144380A1 DETECTION OF ILLICIT ADMINISTRATION OF GROWTH HORMONE 审中-公开
标题翻译：检测生长激素的非法行政管理
公开(公告)号：WO2007144380A1
公开(公告)日：2007-12-21
申请号：PCT/EP2007/055834
申请日：2007-06-13
申请人： NOVO NORDISK HEALTH CARE AG , RASMUSSEN, Michael Højby , CHRISTIANSEN, Jens Sandahl
发明人： RASMUSSEN, Michael Højby , CHRISTIANSEN, Jens Sandahl
IPC分类号： G01N33/74
CPC分类号： G01N33/74 , G01N2333/61 , G01N2333/78 , G01N2333/916
摘要： A method of detecting whether growth hormone (e.g. human growth hormone) has been administered to a human subject comprises: measuring the level of a marker substance chosen among osteocalcin (OST), bone-specific alkaline phosphatase (BAP) and C-terminal telopeptide of type I collagen (CTX) in a blood sample taken from the subject; and comparing the measured level of the marker substance with an average normal baseline level for the marker substance in blood samples taken from human control subjects to whom no administration of growth hormone has taken place prior to the taking of the control blood samples.
摘要翻译：检测生长激素（例如人生长激素）是否已被施用于人受试者的方法包括：测量选自骨钙素（OST），骨特异性碱性磷酸酶（BAP）和C末端肽的标记物质的水平来自受试者的血液样品中的I型胶原（CTX）; 并将所测量的标记物质量与标准物质的平均正常基准水平进行比较，该血液样品取自未服用生长激素的对照受试者在服用对照血液样品之前已经发生。

82. 发明申请

WO2007039475A1 HUMAN COAGULATION FACTOR VII POLYPEPTIDES 审中-公开
标题翻译：人凝血因子VII多肽
公开(公告)号：WO2007039475A1
公开(公告)日：2007-04-12
申请号：PCT/EP2006/066587
申请日：2006-09-21
申请人： NOVO NORDISK HEALTH CARE AG , OLSEN, Ole, Hvilsted , BJELKE, Jais, Rose , PERSSON, Egon
发明人： OLSEN, Ole, Hvilsted , BJELKE, Jais, Rose , PERSSON, Egon
IPC分类号： C12N9/64 , C07K14/745 , A61K38/48
CPC分类号： C12N9/647 , A61K38/00 , C12N9/6437 , C12Y304/21021
摘要： The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
摘要翻译：本发明涉及具有凝固剂活性的新型人凝血因子VIIa变体以及编码此类变体的多核苷酸构建体，包含和表达所述多核苷酸的药物组合物，用途和治疗方法的载体和宿主细胞。

83. 发明申请

WO2006114448A2 A CLOSED CONTAINER COMPRISING AN ACTIVATED FACTOR VII POLYPEPTIDE, PROCESSES FOR THE PREPARATION OF THE SAME, AND A KIT AND A METHOD FOR USE OF THE KIT 审中-公开
标题翻译：包含活化因子VII多肽的封闭容器，其制备方法以及使用试剂盒的方法
公开(公告)号：WO2006114448A2
公开(公告)日：2006-11-02
申请号：PCT/EP2006/061921
申请日：2006-04-28
申请人： NOVO NORDISK HEALTH CARE AG , ARENTSEN, Anne, Charlotte , KÆRSGAARD, Per
发明人： ARENTSEN, Anne, Charlotte , KÆRSGAARD, Per
IPC分类号： A61K9/00 , A61K9/08 , A61K38/37 , A61K38/48 , C12N9/64
CPC分类号： A61K38/4846 , A61K9/0019 , A61K47/02 , A61K47/183 , A61K47/26 , C07K14/745 , C12N9/6437 , C12N9/96 , C12Y304/21021
摘要： The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit.
摘要翻译：本发明涉及一种封闭的容器，其容纳活性因子VII多肽的组合物，其量为每容器体积的2.5-90mg。本发明还涉及用于制备这种封闭容器的各种方法，包括这种容器的试剂盒和使用试剂盒的方法。

84. 发明申请

WO2006089954A2 COMPOUNDS FOR STABILIZING FACTOR VII POLYPEPTIDE FORMULATIONS 审中-公开
标题翻译：稳定因子VII多肽制剂的化合物
公开(公告)号：WO2006089954A2
公开(公告)日：2006-08-31
申请号：PCT/EP2006/060271
申请日：2006-02-24
申请人： NOVO NORDISK HEALTH CARE AG , PETERSEN, Anders, Klarskov , BOWLER, Andrew, Neil
发明人： PETERSEN, Anders, Klarskov , BOWLER, Andrew, Neil
CPC分类号： C07C257/18 , A61K47/02 , A61K47/183 , C07D333/38
摘要： The invention relates to novel compounds with formula (I) and their use in stabilization of Factor VIIa or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof.
摘要翻译：本发明涉及具有式（I）的新化合物及其在稳定因子VIIa或其他因子VII多肽中的用途，特别是在其水性液体组合物中的用途。

85. 发明申请

WO2005123118A1 USE OF FACTOR VIIA OR FACTOR VIIA EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) 审中-公开
标题翻译：因子VIIA或因子VIIA等效物的使用用于预防或减轻侵袭性增生，和/或根据脑内血栓形成（ICH）的EDEMA产生
公开(公告)号：WO2005123118A1
公开(公告)日：2005-12-29
申请号：PCT/EP2005/052890
申请日：2005-06-21
申请人： NOVO NORDISK HEALTH CARE AG , BRUN, Nikolai Constantin , ERHARDTSEN, Elisabeth , SKOLNICK, Brett E.
发明人： BRUN, Nikolai Constantin , ERHARDTSEN, Elisabeth , SKOLNICK, Brett E.
IPC分类号： A61K38/48
CPC分类号： A61K38/4846 , A61K2300/00
摘要： The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients.
摘要翻译：本发明涉及因子VIIa或VIIa因子在制备用于预防ICH患者并发症的药物中的应用。

86. 发明申请

WO2015055692A1 COAGULATION FACTOR VII POLYPEPTIDES 审中-公开
标题翻译：凝血因子VII多糖
公开(公告)号：WO2015055692A1
公开(公告)日：2015-04-23
申请号：PCT/EP2014/072076
申请日：2014-10-15
申请人： NOVO NORDISK HEALTH CARE AG
发明人： ØSTERGAARD, Henrik , GANDHI, Prafull S. , OLSEN, Ole Hvilsted
IPC分类号： C12N9/64 , A61K38/48
CPC分类号： C12N9/6437 , A61K38/00 , A61K38/36 , A61K38/4846 , A61K47/60 , A61K47/61 , A61K47/64 , C07K14/745 , C12Y304/21021
摘要： The present invention relates to modified human coagulation Factor VII polypeptides having coagulant activity, especially variants having higher proteolytic activity and reduced antithrombin reactivity (increased resistance to inactivation by anti-thrombin) when activated as compared to wild-type FVIIa. The variants have certain substitutions at position T293 of mature human FVII in combination with specifc substitutions at L288, W201 and/or K337. The claims are also directed to pharmaceutical compositions, and medical uses of said factor VII polypeptides.
摘要翻译：本发明涉及具有凝血活性的改性人凝血因子VII多肽，特别是与野生型FVIIa相比，当活化时具有较高的蛋白水解活性和降低的抗凝血酶反应性（抗凝血酶失活的抗性增加）的变体。这些变体在成熟人FVII的位置T293与L288，W201和/或K337的特异性取代相结合时具有某些取代。权利要求书还涉及所述因子VII多肽的药物组合物和医学应用。

87. 发明申请

WO2014060401A1 COAGULATION FACTOR VII POLYPEPTIDES 审中-公开
标题翻译：凝血因子VII多糖
公开(公告)号：WO2014060401A1
公开(公告)日：2014-04-24
申请号：PCT/EP2013/071510
申请日：2013-10-15
申请人： NOVO NORDISK HEALTH CARE AG
发明人： STENNICKE, Henning Ralf , OLSEN, Ole Hvilsted , ØSTERGAARD, Henrik
IPC分类号： C12N9/64 , A61K38/48 , A61K47/48
CPC分类号： C12N9/6437 , A61K38/4846 , A61K47/60 , A61K47/61 , A61K47/64 , A61K47/643 , A61K47/644 , C12Y304/21021
摘要： The present invention relates to modified coagulation Factor VII (Factor VII) polypeptides having coagulant activity as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
摘要翻译：本发明涉及具有凝血活性的改性凝血因子VII（因子VII）多肽以及编码这种多肽的多核苷酸构建体，载体和宿主细胞，其包含并表达此类多核苷酸，药物组合物，用途和治疗方法。

88. 发明申请

WO2014006021A1 METHOD OF MANUFACTURING A MEDICAL DEVICE 审中-公开
标题翻译：制造医疗器械的方法
公开(公告)号：WO2014006021A1
公开(公告)日：2014-01-09
申请号：PCT/EP2013/063894
申请日：2013-07-02
申请人： NOVO NORDISK HEALTH CARE AG
发明人： CHRISTENSEN, Ulla Holm
IPC分类号： A61M5/00 , A61J1/20 , B65B55/02 , B65B3/00
CPC分类号： A61J1/2048 , A61J1/201 , A61J1/2089 , A61J1/2096 , A61M5/002 , A61M2207/00 , B65B3/003 , B65B55/027 , F04C2270/0421 , Y10T29/49828
摘要： The invention relates to a method of manufacturing a medical device (1, 299, 399), the method comprising: (i) receiving in a first cleanroom environment categorised by a first airborne particulate cleanliness a plurality of medical components (10, 20, 50, 50', 210, 220, 320, 350) prepared in a second cleanroom environment categorised by a second airborne particulate cleanliness, which is higher than the first airborne particulate cleanliness, where each of the plurality of medical components (10, 20, 50, 50', 210, 220, 320, 350) comprises a sealed surface portion, (ii) assembling at least the plurality of medical components (10, 20, 50, 50', 210, 220, 320, 350) in the first cleanroom environment, thereby providing a sub-assembly, and (iii) establishing an enclosure for the sub-assembly capable of maintaining an internal airborne particulate cleanliness equivalent to the first airborne particulate cleanliness.
摘要翻译：本发明涉及一种制造医疗装置的方法，该方法包括：（i）在由第一空气中的颗粒清洁度分类的第一洁净室环境中接纳多个医疗部件（10,20,50），50'，210,220,320,350），其被制备在由第二空气中的颗粒清洁度分类的第二洁净室环境中，所述第二空气中的颗粒清洁度高于所述第一空气中的颗粒清洁度，其中所述多个医疗部件（10,20,50 ，50'，210,220,320,350）包括密封表面部分，（ii）将至少所述多个医疗部件（10,20,50,50'，210,220,320,350）组装在所述第一洁净室环境，从而提供子组件，以及（iii）建立能够保持与第一空气中的颗粒清洁度相当的内部空气中的颗粒清洁度的子组件的外壳。

89. 发明申请

WO2011089255A1 GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY 审中-公开
标题翻译：生长激素与增长的内生效果
公开(公告)号：WO2011089255A1
公开(公告)日：2011-07-28
申请号：PCT/EP2011/050923
申请日：2011-01-24
申请人： NOVO NORDISK HEALTH CARE AG , BEHRENS, Carsten , JOHANSEN, Nils, Langeland , ANDERSEN, Henrik, Sune , NØRSKOV-LAURITSEN, Leif , BUCHARDT, Jens
发明人： BEHRENS, Carsten , JOHANSEN, Nils, Langeland , ANDERSEN, Henrik, Sune , NØRSKOV-LAURITSEN, Leif , BUCHARDT, Jens
IPC分类号： A61K47/48 , A61P5/00
CPC分类号： C12N15/70 , A61K47/54 , A61K47/542 , A61K47/545 , C07K14/61 , G01N2030/027
摘要： The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
摘要翻译：本发明涉及具有延长轮廓的生长激素化合物。通过将白蛋白结合残基通过亲水间隔物连接到生长激素变体来获得该效果。进一步描述了制备和使用这些化合物的方法。这些生长激素化合物是基于被认为在治疗中特别有用的悬浮状态。

90. 发明申请

WO2011015649A1 GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY 审中-公开
标题翻译：生长激素具有广泛的内生效应
公开(公告)号：WO2011015649A1
公开(公告)日：2011-02-10
申请号：PCT/EP2010/061473
申请日：2010-08-06
申请人： NOVO NORDISK HEALTH CARE AG , JOHANSEN, Nils, Langeland , ANDERSEN, Henrik, Sune , BUCHARDT, Jens , BEHRENS, Carsten , NØRSKOV-LAURITSEN, Leif , SU, Jing
发明人： JOHANSEN, Nils, Langeland , ANDERSEN, Henrik, Sune , BUCHARDT, Jens , BEHRENS, Carsten , NØRSKOV-LAURITSEN, Leif , SU, Jing
IPC分类号： A61K47/48 , A61P5/06
CPC分类号： A61K47/48246 , A61K47/54 , A61K47/542 , A61K47/543 , A61K47/545 , A61K47/60 , A61K47/64
摘要： The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
摘要翻译：本发明涉及针对皮下给药优化的多肽化合物，例如具有提供与白蛋白非共价结合的接头的生长激素缀合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式